Rhabdoid tumor signs - Causes, Treatment & When to See a Doctor

What is Rhabdoid tumor signs?

A rhabdoid tumor is a rare, aggressive malignancy that most commonly arises in the kidney (called malignant rhabdoid tumor of the kidney, MRTK) or in the central nervous system (called AT/RT – atypical teratoid/rhabdoid tumor). Although the tumor itself is the disease, the term “rhabdoid tumor signs” refers to the collection of clinical findings that prompt a physician to suspect a rhabdoid tumor. These signs can include palpable masses, neurologic deficits, unexplained weight loss, or laboratory abnormalities. Early recognition is crucial because these tumors grow rapidly and often present at an advanced stage.

Rhabdoid tumors are most frequently diagnosed in infants and young children (under 3 years of age), but cases have been reported in adolescents and even adults. The underlying cause is usually a somatic or germ‑line mutation in the SMARCB1 (also known as INI1) or, less often, SMARCA4 genes, which are important for chromatin remodeling and tumor suppression [CDC, Mayo Clinic].

Common Causes

While rhabdoid tumors themselves are primary cancers, several underlying conditions or risk factors can predispose a person to develop them or mimic their signs. The most relevant include:

• Germ‑line SMARCB1 (INI1) mutation – hereditary predisposition (Rhabdoid Tumor Predisposition Syndrome).
• Somatic SMARCB1 loss – acquired mutation in kidney or brain tissue.
• Congenital anomalies – such as hemihypertrophy, which increase risk for embryonal tumors.
• Radiation exposure – prior therapeutic radiation (rare in children) can predispose to secondary rhabdoid‑type tumors.
• Immunodeficiency – severe combined immunodeficiency (SCID) or HIV‑related immunosuppression may allow rapid tumor growth.
• Other pediatric embryonal tumors – e.g., Wilms tumor, which can coexist and confound the clinical picture.
• Genetic syndromes – such as Beckwith‑Wiedemann syndrome, which carries a higher risk of renal tumors.
• Environmental toxins – limited data suggest possible association with parental occupational exposures.
• Previous chemotherapy – rare cases of therapy‑related rhabdoid features.
• Metastatic disease from other primary sites – sometimes rhabdoid morphology appears in metastases, complicating diagnosis.

Associated Symptoms

Because rhabdoid tumors can arise in different organs, the accompanying symptoms vary. The most frequently reported signs across locations include:

• Palpable abdominal or flank mass – especially in infants with kidney involvement.
• Hematuria – blood in the urine, indicating renal invasion.
• Abdominal pain or distension – due to tumor growth or obstruction.
• Neurologic deficits – headaches, vomiting, seizures, or focal weakness in AT/RT.
• Rapid weight loss or failure to thrive – common in aggressive malignancies.
• Fever of unknown origin – may reflect tumor necrosis or paraneoplastic inflammation.
• Elevated lactate dehydrogenase (LDH) and uric acid – laboratory markers of tumor burden.
• Hypertension – secondary to renal artery compression.
• Respiratory distress – when the tumor invades the thoracic cavity or causes metastatic lung nodules.

When to See a Doctor

Any of the following situations should prompt immediate medical evaluation, even if the child or adult appears otherwise well:

• New, firm abdominal or neck mass that is growing rapidly.
• Persistent headache, vomiting, or changes in vision, especially in a child under 5 years.
• Unexplained blood in urine or persistent urinary symptoms.
• Unexplained fever, weight loss, or night sweats lasting more than 2 weeks.
• Sudden neurologic changes – seizures, weakness, or difficulty with balance.
• Signs of high blood pressure in a young child (e.g., irritability, nosebleeds).

Early referral to a pediatric oncologist or a specialized cancer center dramatically improves the chance of curative treatment.

Diagnosis

The diagnostic work‑up for suspected rhabdoid tumor includes a combination of imaging, laboratory tests, and tissue analysis.

1. Imaging Studies

• Ultrasound – first‑line for abdominal masses in infants; can detect solid vs. cystic components.
• Contrast‑enhanced CT scan – delineates size, local invasion, and metastatic spread.
• MRI of the brain and spine – essential for AT/RT to evaluate intracranial lesions.
• Chest CT – screens for pulmonary metastases.
• PET‑CT – useful in staging and assessing treatment response.

2. Laboratory Evaluation

• Complete blood count (CBC) – may reveal anemia or thrombocytopenia.
• Serum chemistry – LDH, uric acid, renal function tests.
• Urinalysis – checking for hematuria or protein.
• Genetic testing – multiplex PCR or next‑generation sequencing for SMARCB1 or SMARCA4 mutations, especially if a hereditary syndrome is suspected.

3. Tissue Diagnosis

The gold standard is a biopsy (core or excisional) examined by a pediatric pathologist.

• Histology – sheets of large, eosinophilic cells with eccentric nuclei, prominent nucleoli, and abundant cytoplasmic inclusions (the “rhabdoid” appearance).
• Immunohistochemistry (IHC) – loss of INI1 (SMARCB1) nuclear staining is a hallmark; other markers include vimentin, EMA, and cytokeratins.
• Molecular studies – confirmatory detection of SMARCB1/SMARCA4 deletions or mutations.

4. Staging

Staging follows the Children’s Oncology Group (COG) or International Rhabdoid Tumor Consortium guidelines, integrating tumor size, nodal involvement, distant metastases, and molecular risk factors.

Treatment Options

Because rhabdoid tumors are highly aggressive, treatment is multimodal and typically occurs at specialized centers.

1. Surgery

• Radical nephrectomy for renal tumors when feasible.
• Gross total resection of CNS lesions, aiming for >95% removal.
• Inoperable disease may be debulked to relieve symptoms.

2. Chemotherapy

Intensive, multi‑agent regimens are standard. Common protocols (adapted from COG studies) include:

• Vincristine, cyclophosphamide, doxorubicin (VAC).
• Ifosfamide and etoposide.
• High‑dose methotrexate with leucovorin rescue.
• Platinum agents (carboplatin or cisplatin) for CNS disease.

Neoadjuvant (pre‑surgical) chemotherapy can shrink tumors, making resection safer.

3. Radiation Therapy

• Localized external‑beam radiation for residual disease after surgery.
• Proton therapy may reduce long‑term toxicity in children.

4. Targeted and Immunotherapies (Emerging)

• EZH2 inhibitors – show promise in pre‑clinical models with SMARCB1 loss.
• CDK4/6 inhibitors – under investigation in early‑phase trials.
• Immune checkpoint inhibitors have limited data but are being explored for refractory cases.

5. Supportive & Home Care

• Management of chemotherapy side effects: anti‑emetics, growth‑factor support (e.g., G‑CSF), and hydration to prevent tumor lysis syndrome.
• Nutrition: high‑calorie, high‑protein diet; consider enteral feeding if oral intake is poor.
• Pain control: acetaminophen, NSAIDs, or opioids as prescribed.
• Psychosocial support: counseling, support groups, and educational resources for families.

Prevention Tips

Because most rhabdoid tumors arise from spontaneous genetic mutations, true primary prevention is limited. However, some steps can reduce risk or facilitate early detection:

• Genetic counseling for families with known SMARCB1 mutations or a history of rhabdoid tumors.
• Routine pediatric well‑child visits with careful abdominal examination.
• Prompt evaluation of any persistent abdominal mass, unexplained hematuria, or neurologic change.
• Avoid unnecessary radiation exposure in children; use ultrasound or MRI when feasible.
• Maintain a healthy prenatal environment – adequate folate intake and avoidance of known teratogens.

Emergency Warning Signs

These situations require immediate medical attention—call emergency services or present to the nearest hospital emergency department without delay.

---

References: CDC – Rhabdoid Tumor Fact Sheet; Mayo Clinic – AT/RT; National Cancer Institute – Malignant Rhabdoid Tumor; Cleveland Clinic – AT/RT. Information reviewed July 2024.